➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Johnson and Johnson
Merck
Colorcon
AstraZeneca

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Litigation Details for Swanson v. Alza Corporation (N.D. Cal. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Swanson v. Alza Corporation (N.D. Cal. 2012)

Docket   Start Trial Date Filed 2012-08-30
Court District Court, N.D. California Date Terminated 2015-05-21
Cause 28:1338 Patent Infringement Assigned To Phyllis Jean Hamilton
Jury Demand Plaintiff Referred To Kandis A. Westmore
Parties ALZA CORPORATION; DR. JAMES M. SWANSON; DR. MARCEL KINSBOURNE
Patents 6,919,373; 6,930,129; 8,163,798
Attorneys Alan Scott Levin; Allison Elizabeth Kerndt; Bryan John Boyle; Courtney Roberts Forrest; Elena Maria DiMuzio; George Frank Pappas; Gerald P. Dodson; Jessica Parezo; Kent Brian Bathurst; Kurt G. Calia; Michael Tenkku Adelsheim; Richard Anthony Lopez; Robert Joseph Yorio
Firms Attorney at Law; Carr & Ferrell LLP; Carr and Ferrell LLP; Covington & Burling; Covington & Burling LLP; Covington and Burling LLP, One City Center
Link to Docket External link to docket
Small Molecule Drugs cited in Swanson v. Alza Corporation
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Swanson v. Alza Corporation (N.D. Cal. 2012)

Date Filed Document No. Description Snippet Link To Document
2014-04-25 157 17 U.S. Patent No. 6,919,373 B1 (“the ‘373 patent”). He also asserts that the patents-in-suit …,930,129 B2 (“the ‘129 patent”); U.S. Patent No. 8,163,798 B2 (“the ‘798 patent”); and … 15 patents that are presently assigned to defendant ALZA Corporation (“ALZA”) – U.S. Patent … 23 covered by several patents, including the patents-in-suit. … The '129 patent was issued on August 16, 2005, and the '798 patent was issued on External link to document
2015-03-20 245 22 6,930,129 B2 (“the ‘129 patent,” issued August 16, 2005), and U.S. Patent No. 8,163,798 … 28 6,930,129 and 8,163,798 as construed by the court do not…;129 patent, and that he is at least a co-inventor of the '129 patent and the '798 patent. …co-inventor of the '129 patent and the '798 patent. With regard to the '129 patent, he …adults. Concerta® is covered by several patents, including U.S. Patent No. External link to document
2013-03-12 55 26 6,919,373 B1 (“the ‘373 patent”). In the present action, Dr. Swanson… (“the ‘129 patent”); U.S. Patent No. 8,163,798 B2 (“the ‘798 patent”); and U.S. Patent No. … 24 patents that are presently assigned to defendant ALZA – U.S. Patent No. 6,930,129 B2 …had an opportunity to file patent applications. ALZA filed provisional patent applications on … 3 8, 2001 (now the ‘129 patent). The ‘373 patent was issued July 19, 2005. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
Moodys
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.